CompletedPhase 2

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

182 participantsStarted 2016-12-02

Plain-language summary

This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have an involved body surface area (BSA) ≥10% and
✓. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and
✓. Have a Static Physician Global Assessment (sPGA) score of ≥3.

Exclusion criteria

✕. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)
✕. current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
✕. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigator's judgment

What they're measuring

Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)

Timeframe: Week 16

Trial details

NCT IDNCT03000075

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-09-21

Results submitted2018-09-06

View on ClinicalTrials.gov More Psoriasis trials